Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

Summary

The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.

Eligibility

Inclusion Criteria for LPS patients cohort:

Men/women older than 18 years old,

Surgery for :

* Localized WD-LPS and DD-LPS, and/or
* WD-LPS or DD-LPS local relapse, and/or
* WD-LPS or DD-LPS distant relapse and/or
* Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent

Inclusion Criteria for healthy subjects cohort:

Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort

Exclusion Criteria:

Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma.

Pregnancy and/or feeding

Conditions3

Browse More Trials